Which anticoagulant and what dose should be restarted in a patient after intracerebral hemorrhage, based on age, body weight, and serum creatinine?

Anticoagulant Selection and Dosing After Intracerebral Hemorrhage

Resume anticoagulation approximately 3 weeks (20-22 days) after intracerebral hemorrhage with a direct oral anticoagulant (DOAC) rather than warfarin, using dose adjustments based on age, weight, and renal function as specified below.

Timing of Anticoagulation Resumption

The optimal window for restarting anticoagulation is 20-22 days post-ICH 1. This timing minimizes both rebleeding risk (lowest after day 7.5) and thromboembolic events (increasing significantly after day 30). Starting earlier than 7 days substantially increases hemorrhagic complications, while delaying beyond 4 weeks elevates ischemic stroke risk, particularly in high-risk patients (CHA₂DS₂-VASc ≥4) 2.

Anticoagulant Selection

Choose a DOAC over warfarin for the following reasons:

• Lower intracranial hemorrhage rates across all DOACs compared to warfarin 3, 4
• More predictable pharmacokinetics without need for INR monitoring
• Reduced fatal bleeding events 3

Avoid warfarin unless the patient has:

• Mechanical heart valve prosthesis 2
• Moderate-to-severe mitral stenosis 2
• Left ventricular assist device 2

DOAC Selection and Dosing

Apixaban (Preferred Option)

Standard dose: 5 mg twice daily

Reduce to 2.5 mg twice daily if patient has ANY TWO of the following 5:

• Age ≥80 years
• Body weight ≤60 kg
• Serum creatinine ≥1.5 mg/dL (≥133 μmol/L)

Also reduce to 2.5 mg twice daily if:

• Creatinine clearance 15-29 mL/min 5

Rationale: Apixaban demonstrated superior efficacy and safety in ARISTOTLE trial with significantly lower rates of stroke, major bleeding, intracranial hemorrhage, and all-cause mortality compared to warfarin 3. The dose reduction criteria are evidence-based from the pivotal trial.

Rivaroxaban (Alternative)

Standard dose: 20 mg once daily

Reduce to 15 mg once daily if:

• Creatinine clearance 15-50 mL/min 5

Note: Rivaroxaban showed higher gastrointestinal bleeding than apixaban, making it less ideal post-ICH 3.

Edoxaban (Alternative)

Standard dose: 60 mg once daily

Reduce to 30 mg once daily if ANY of the following 5:

• Body weight ≤60 kg
• Creatinine clearance ≤50 mL/min
• Concomitant strong P-glycoprotein inhibitor

Dabigatran (Less Preferred)

Standard dose: 150 mg twice daily

Reduce to 110 mg twice daily if 4:

• Age ≥80 years
• Creatinine clearance 30-50 mL/min
• Increased bleeding risk

Reduce to 75 mg twice daily (US only) if:

• Creatinine clearance 15-30 mL/min 6

Caution: Dabigatran has highest rates of dyspepsia and gastrointestinal bleeding among DOACs 4. The 75 mg dose was not tested in RE-LY trial 6.

Critical Considerations for Post-ICH Patients

High Rebleeding Risk Factors

Patients with NOAC use prior to ICH have 16-fold increased risk of hemorrhagic complications upon resumption 1. In these cases:

• Consider switching to a different DOAC
• Ensure strict adherence to dose reduction criteria
• Monitor closely in first 3 months

Age-Specific Concerns

Patients ≥80 years have 4.3-fold increased risk of ischemic events if anticoagulation is delayed 1. This population requires:

• Dose reduction for apixaban (if meets 2/3 criteria) or dabigatran
• Earlier resumption (closer to day 20 rather than day 30)
• No dose reduction needed for rivaroxaban unless renal impairment present

Renal Function Monitoring

Calculate creatinine clearance, not just serum creatinine - renal function decreases approximately 0.7 mL/min per year with aging 7. Serum creatinine alone underestimates renal dysfunction in elderly patients.

Contraindications:

• All DOACs contraindicated if creatinine clearance <15 mL/min 7
• Edoxaban contraindicated if creatinine clearance >95 mL/min (increased stroke risk) 6

High Thrombotic Risk Scenarios

If patient has CHA₂DS₂-VASc ≥4 or recent stroke/TIA within 3 months 2:

• Consider bridging with intravenous unfractionated heparin starting day 7-10 post-ICH
• Transition to DOAC at day 20-22
• UFH preferred over LMWH due to short half-life and reversibility with protamine 2

What NOT to Do

• Do not use prophylactic-dose anticoagulation long-term - provides inadequate stroke prevention while maintaining bleeding risk
• Do not delay beyond 4 weeks in high-risk patients - ischemic complications increase substantially 1
• Do not resume warfarin unless absolute indication exists - consistently higher ICH rates than DOACs 3, 4
• Do not underdose based on fear - subtherapeutic anticoagulation increases thrombotic risk without eliminating bleeding risk